United Therapeutics Corporation Prices $210 Million Convertible Senior Notes

SILVER SPRING, Md., Oct. 24 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR - News) today announced the pricing of $210 million principal amount of Convertible Senior Notes due 2011 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). In addition, United Therapeutics announced that the initial purchaser has exercised its option to purchase a $40 million principal amount of additional notes to cover overallotments in full. United Therapeutics estimates that the net proceeds from this offering (including proceeds resulting from exercise of the initial purchaser's option) will be approximately $242 million, after deducting the initial purchaser's discounts and commissions and estimated expenses.